01—Abstract
Summary
Summary of the 10-K filed February 23, 2012. Cited figures are marked; the original filing is the authoritative source.
Gilead Sciences, Inc. reported robust growth in its 2011 fiscal year, with total revenues reaching $8.39 billiona, a 5% increase year-over-year, primarily driven by a 10% rise in product sales to $8.10 billion.
The company's antiviral franchise, particularly sales of Atripla and Truvada, was the main growth engine. Gilead also made significant strategic moves, highlighted by the pending $11.1 billionb acquisition of Pharmasset, Inc., aimed at strengthening its position in the hepatitis C market with the acquisition of the promising drug candidate GS-7977. The company is actively managing its pipeline, with advancements in HIV treatments including the submission of a new drug application for the 'Quad' single-tablet regimen and the launch of Complera/Eviplera.
While facing increasing competition and ongoing pricing pressures, especially in Europe, Gilead demonstrated strong financial management, with a significant increase in cash reserves and continued stock repurchase programs. Investors should note the ongoing legal challenges related to patent defenses for key products and the potential impact of U.S. healthcare reform on future revenue and profitability.
02—Key points
Key Highlights
- Total revenues grew 5% to $8.39 billion in 2011, with product sales increasing 10% to $8.10 billion, primarily driven by the antiviral franchise.
- Gilead announced a $11.1 billion acquisition of Pharmasset, Inc., to bolster its Hepatitis C (HCV) pipeline with the addition of GS-7977, a highly potent nucleotide analog.
- The HIV franchise continues to be a strong performer, with significant sales growth from Atripla and Truvada, and the launch of Complera/Eviplera, with the 'Quad' single-tablet regimen awaiting FDA approval.
- Research and Development (R&D) expenses increased by 15% to $1.23 billion in 2011, reflecting investments in clinical studies and strategic acquisitions.
- The company's cash, cash equivalents, and marketable securities significantly increased to $9.96 billion by the end of 2011, partly due to debt financing for the Pharmasset acquisition.
- Gilead is actively engaged in patent litigation to defend its key products against generic manufacturers, which could impact future revenues if unsuccessful.
- The company highlighted its commitment to global access through various programs, including providing HIV and other medicines at reduced prices in developing countries.
03—One dollar
Follow one dollar
Of each $1.00 of revenue in FY2011, Gilead Sciences, Inc. kept $0.33.
- Revenue$8.39B100.0%
- Cost of revenue−$2.12B25.3%
- Gross profit$6.26B74.7%
- Operating costs−$2.47B29.5%
- Operating income$3.79B45.2%
- Interest, other & tax−$986.2M11.8%
- Net income$2.80B33.4%
Where FY2011 revenue went
$8.39B- Net income: $2.80B, 33% of revenue
- Cost of revenue: $2.12B, 25% of revenue
- SG&A: $1.24B, 15% of revenue
- R&D: $1.23B, 15% of revenue
- Interest, other & tax: $986.2M, 12% of revenue
Kept 33% as net income
Full revenue history →04—Financials
Financial Highlights
Figures from 10-KFY2011filed February 23, 2012Financial Statements
FY2011 against FY2010
| Line item | FY2011FY2010 | Change |
|---|---|---|
| Revenue | $8.39B$7.95B | +5.5% |
| Cost of Revenue | $2.12B$1.87B | +13.6% |
| Gross Profit | $6.26B$6.08B | +3.0% |
| R&D Expenses | $1.23B— | — |
| SG&A Expenses | $1.24B$1.04B | +18.9% |
| Operating Expenses | $4.60B$3.99B | +15.3% |
| Operating Income | $3.79B$3.96B | −4.4% |
| Interest Expense | $205.42M$108.96M | +88.5% |
| Net Income | $2.80B$2.90B | −3.4% |
| EPS (Basic) | $1.81$1.69 | +7.1% |
| EPS (Diluted) | $1.77$1.66 | +6.6% |
| Shares Outstanding (Basic) | 1.55B1.71B | −9.5% |
| Shares Outstanding (Diluted) | 1.58B1.75B | −9.5% |
05—Questions
Frequently Asked Questions
What were Gilead's key financial achievements in 2011?
In 2011, Gilead reported total revenues of $8.39 billion, a 5% increase from 2010. Product sales grew 10% to $8.10 billion, mainly driven by its antiviral products like Atripla and Truvada. Net income was $2.80 billion.
What is the significance of the Pharmasset acquisition for Gilead?
Gilead announced the $11.1 billion acquisition of Pharmasset, which closed in early 2012. This strategic move significantly strengthens Gilead's position in the Hepatitis C (HCV) market by acquiring Pharmasset's lead drug candidate, GS-7977, a promising nucleotide analog with potential for treating HCV across different genotypes.
How is Gilead addressing its HIV portfolio and pipeline?
Gilead's HIV franchise remains a strong performer, with continued sales growth from Atripla and Truvada. The company also launched Complera/Eviplera, its second single-tablet regimen for HIV, and submitted a new drug application for the 'Quad' single-tablet regimen to the FDA, anticipating approval in 2012. These advancements aim to provide more convenient treatment options for HIV patients.
What are the main risks and challenges highlighted in the report?
Key risks include intense competition in the biopharmaceutical market, potential pricing pressures from government and private payers, patent expirations and generic competition, regulatory hurdles, and the outcomes of ongoing patent litigation. The company also noted the potential impact of U.S. healthcare reform and economic conditions in Southern Europe on its financial performance.
06—Continue